Trial Profile

A Phase 2, Two-Part, Multiple-Ascending-Dose Study of SRP-5051 for Dose Determination, Then Dose Expansion, in Patients With Duchenne Muscular Dystrophy Amenable to Exon 51-Skipping Treatment

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 12 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SRP-5051 (Primary)
Indications Duchenne muscular dystrophy
Focus Adverse reactions; Proof of concept; Registrational; Therapeutic Use
Acronyms MOMENTUM
Sponsors Sarepta Therapeutics

Most Recent Events

10 Mar 2025 Status changed from active, no longer recruiting to discontinued.
29 Jan 2024 According to a Sarepta Therapeutics media release, Eugenio Mercuri M.D., Ph.D., head of the Neuromuscular Unit, Catholic University, Rome, Italy, is an investigator in the study.
29 Jan 2024 Results (till date; High Dose and Low dose results at 28 weeks) published in a Sarepta Therapeutics media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com